Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes' - 2World leaders, rights groups react to COP30 climate deal
- 3'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
- 4Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
- 5Pick Your Favored sort of cooking
- Vote In favor of Your Favored Treat
- Michael Jordan donates $10M to North Carolina medical center in honor of his mother
- 19 Peculiar Films You Shouldn't Watch With Your Mum
- Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- How Trump's marijuana executive order could change medical research landscape
- Benihana is 60 years old. Gen Z is lining up.
- Popular Film Areas: A Worldwide Manual for Film Enchantment
- Step by step instructions to Pick A Pre-owned vehicle Stage
